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Background: The optimal radiation dose for treating esophageal 
squamous cell carcinoma (ESCC) has long been debated. We evalu-
ated if doses greater than 50.4 Gy delivered with modern techniques 
are beneficial in terms of tumor control, survival, and toxicity.
Methods: We included 193 consecutive patients with ESCC treated with 
definitive concurrent chemoradiotherapy from 1998 to 2012. Patients 
were treated to a dose of ≤50.4 Gy (low-dose, n = 137) or greater than 
50.4 Gy (high-dose, n = 56). Tumor response, local-regional control, 
survival, and treatment toxicity were compared between groups.
Results: High-dose group had a significantly lower local failure rate 
(17.9% versus 34.3%, p = 0.024) and a marginal better 5-year local-
regional failure-free survival (68.7% versus 55.9%, p = 0.052) than the 
low-dose group. No significant differences were found between high- and 
low-dose groups in tumor complete response rate (p = 0.975), regional 
failure rate (p = 0.336), distant metastasis rate (p = 0.390), or 5-year over-
all survival (p = 0.617). No difference in the incidence of toxic effects was 
observed between the two groups except for grade 3 skin reaction (12.5% 
[high] versus 2.2% [low], p < 0.001) and grade greater than or equal to 3 
esophageal stricture (32.1% [high] versus 18.2% [low], p = 0.037).
Conclusions: Local tumor control might be improved by higher dose 
of greater than 50.4 Gy, when delivered with modern techniques and 
concurrent chemotherapy, at the consequence of increased toxicity 
without impact on overall survival.
Key Words: Esophageal squamous cell carcinoma, Radiation dos-
age, Chemoradiotherapy.
(J Thorac Oncol. 2014;9: 1398–1405)
Concurrent chemoradiotherapy (CRT) followed by sur-gery is widely accepted as the standard treatment for 
locally advanced esophageal cancer.1,2 With the develop-
ment of more advanced radiation techniques and chemo-
therapy regimens, the question has been raised as to whether 
high-dose radiotherapy given concurrently with effective 
chemotherapy could achieve similar or better survival rates 
compared with the standard treatment, especially for esopha-
geal squamous cell carcinoma (ESCC).3–5 The optimal radia-
tion dose for definitive treatment of ESCC, however, remains 
in debate, particularly in light of the ability of modern radia-
tion techniques to safely and effectively deliver higher radia-
tion doses.6–8
Some groups maintain that a dose of 60 to 70 Gy is 
needed to control gross ESCC tumors.9 However, the results 
of the Radiation Therapy Oncology Group (RTOG) trials 
85-0110 and RTOG 94-0511 led to the adoption of concurrent 
CRT to a total dose of 50.4 Gy given in conventional fractions 
as the standard protocol. Investigators continue to debate the 
contribution of outdated radiation techniques to these results. 
Moreover, in RTOG 94-05, the longer treatment time and the 
lower fluorouracil dose in the high-dose group may also have 
contributed to the lack of superiority of the high (64.8 Gy) 
dose over the lower (50.4 Gy) dose in terms of local control 
and survival.11–13
On the contrary, a review of neoadjuvant concurrent 
CRT trials for esophageal carcinoma showed evidence of a 
dose-response relationship between increasing radiation dose 
and pathologic complete response (pCR) rate in a dose range of 
20 to 60 Gy.14 A retrospective study also revealed that patients 
with stage II to III esophageal cancer treated with concurrent 
CRT with a radiation dose greater than 51 Gy (54–64.8 Gy) 
had better local-regional control and survival than did those 
treated with a lower dose (≤51 Gy).12 Other studies found that 
doses of 50 to 65 Gy given concurrently with chemotherapy 
may improve local control and overall survival (OS) relative 
to low-dose radiation (≤50 Gy) for cervical and upper thoracic 
esophageal carcinoma.15,16
Given these discrepancies on the best radiation dose for 
definitive therapy for ESCC, we retrospectively analyzed 193 
ESCC patients who underwent definitive CRT, using modern 
radiation delivery techniques, at a single institution to deter-
mine whether dose escalation above 50.4 Gy is beneficial in 
terms of tumor control or survival.
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PATIENTS AND METHODS
Patient Selection
All patients had histologically proven primary ESCC. 
Patients with prior malignancies or severe uncontrolled medi-
cal conditions and those who underwent surgery after CRT 
were excluded, leaving a total of 193 patients with ESCC 
who received concurrent CRT as definitive therapy from May 
1998 through May 2012 for this analysis. Treatment records 
and hospital charts were reviewed for baseline (pretreatment) 
and treatment characteristics, toxicity during and after ther-
apy, and tumor control and survival outcomes. This study was 
approved by the appropriate institutional review board.
Pretreatment Evaluations
Disease in all cases was staged (or restaged) according 
to the sixth (2002) edition of the American Joint Committee 
on Cancer (AJCC) staging manual for esophageal carcinoma. 
Pretreatment evaluations included a medical history and phys-
ical examination, upper gastrointestinal double-contrast bar-
ium radiography, esophagogastroduodenoscopy (EGD) with 
endoscopic ultrasonography and biopsy, computed tomog-
raphy scan of the chest and abdomen, and positron emission 
tomography (PET) when available. Of the 193 patients, 150 
(77.7%) cases were PET-staged.
Treatment Approaches
Radiation had been delivered by three-dimensional con-
formal radiation therapy, intensity-modulated radiation ther-
apy, or proton beam therapy. The clinical target volume (CTV) 
included the gross primary tumor volume with a radial margin 
of 0.5 to 1 cm and a proximal and distal margin of 3 to 4 cm 
and also covered the regional nodal regions. The nodal CTV 
was defined by a 0.5- to 1-cm expansion around the nodal 
gross tumor volume. The planning target volume (PTV) was 
the CTV plus a uniform 0.5-cm expansion margin. For both 
the low-dose (≤50.4 Gy) and high-dose (≥54–66 Gy) groups, 
prescribed dose is given to the PTV. All patients received pla-
tin- or taxane-based chemotherapy with fluorouracil, given 
weekly during the radiotherapy.
Evaluations During and After Therapy
During therapy, symptoms and blood test results were 
closely monitored and esophagography was done every 2 weeks. 
Evidence of acute toxicity was assessed weekly during CRT and 
every 2 weeks for 90 days after the completion of CRT. Clinical 
response to treatment was evaluated based on the results of 
EGD, biopsy (when available), computed tomography scan of 
chest and abdomen, and PET (when available) at 0 to 3 months 
after the completion of CRT. Patients usually underwent follow-
up examinations including EGD and imaging studies every 3 
months for the first year and every 6 months thereafter. EGD 
with biopsy was done when local-regional failure was suspected, 
and all the local-regional failure was histologically proven.
Outcomes
Tumor response and treatment toxicities were evaluated 
according to the Response Evaluation Criteria in Solid Tumors 
(RECIST) system17 and the Common Terminology Criteria for 
Adverse Events (CTCAE) version 3.0.18 Complete response 
on PET was defined as the lack of uptake of fluorodeoxyglu-
cose on the PET scan after treatment.19 Local/regional failure 
was defined as the persistence or recurrence of the primary 
tumor and regional lymph nodes, whereas distant failure 
was defined as the metastasis to any site beyond the primary 
tumor and regional lymph nodes. Distant metastasis–free sur-
vival (DMFS), local-regional failure-free survival (LRFFS), 
disease-free survival (DFS), and OS were defined as the time 
from the end of CRT to tumor metastasis, local-regional tumor 
persistence or recurrence, the first evidence of any treatment 
failure, and death from any cause, respectively.
Statistical Analysis
Patients were stratified by the total radiation dose (low-
dose group ≤50.4 Gy and high-dose group >50.4 Gy). Statistical 
analysis was done with SPSS standard version 16.0 (SPSS Inc., 
Chicago, IL). Fisher’s exact texts were used to assess measures 
of association in frequency tables. DMFS, LRFFS, DFS, and 
OS were assessed with the Kaplan-Meier method and curves 
compared with log-rank tests. The Cox regression model was 
used for multivariate analysis to assess the effect of patient 
characteristics and other factors on the endpoints. Statistical 
tests were based on a two-sided significance level, and p values 
of less than 0.05 were considered significant.
RESULTS
Patient Characteristics
The characteristics of the 193 patients are summarized 
in Table 1. The radiation dose per fraction ranged from 1.6 to 
2.4 Gy, while 90.2% of the radiation treatments were deliv-
ered in conventional fractions. Except one case who only 
received 41.4 Gy/23 F because she refused the last two frac-
tions of treatment for her grade 3 toxicity and good treatment 
response, all the other patients received a total dose of 45 to 
66 Gy. In terms of treatment completion, 97.8% (134) and 
98.2% (55) of the low-dose and high-dose groups completed 
the radiotherapy without any delays longer than 3 days, and 
78.1% (107 in low) and 76.8% (43 in high) of the two groups 
received the planned chemotherapy without dose reduction. 
Higher radiation doses (>50.4 Gy) were more often delivered 
to proximal ESCCs by intensity-modulated radiation therapy, 
whereas the lower doses (≤50.4 Gy) were more often given to 
middle/distal ESCCs by three-dimensional conformal radia-
tion therapy or proton therapy (p < 0.001, Table 1). No sig-
nificant differences were found between the two groups in 
other clinicopathologic variables, including general character-
istics, receiving induction chemotherapy or not and treatment 
response (p > 0.05, Table 1).
Patterns of Failure
During the median observation period of 32.4 months 
(range 2.5‒161.3 months) for all patients (45.9 months [range 
3.6‒148 months] for those alive at the time of analysis), 69 
experienced local-regional failure, 59 distant metastasis, and 
123 death. Of the 69 patients who had local-regional failure 
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TABLE 1.  Patient, Disease, and Treatment Characteristics
Characteristic








Age at diagnosis (yr) 0.910
  Median (range) 68 (30–89) 68 (30–86) 68.5 (45–89)
Sex 0.149
  Female 82 (42.5) 63 (46.0) 19 (33.9)
  Male 111 (57.5) 74 (54.0) 37 (66.1)
Ethnicity 0.292
  Caucasian 149 (77.2) 102 (74.5) 47 (83.9)
  African American 20 (10.4) 16 (11.7) 4 (7.1)
  Hispanic 12 (6.2) 8 (5.8) 4 (7.1)
  Asian 12 (6.2) 11 (8.0) 1 (1.8)
Smoked at diagnosis 0.081
  No 136 (70.5) 102 (74.5) 34 (60.7)
  Yes 57 (29.5) 35 (25.5) 22 (39.3)
Karnofsky performance score 0.616
  90–100 65 (33.7) 48 (35.0) 17 (30.4)
  ≤80 128 (66.3) 89 (65.0) 39 (69.6)
Tumor locationa <0.001
  Proximal 66 (34.2) 32 (23.4) 34 (60.7)
  Middle 40 (20.7) 31 (22.6) 9 (16.1)
  Distal 87 (45.1) 74 (54.0) 13 (23.2)
Tumor differentiation 0.562
  Well 8 (4.1) 7 (5.1) 1 (1.7)
  Moderate 105 (54.4) 76 (55.5) 29 (51.8)
  Poor 77 (39.9) 53 (38.7) 24 (42.9)
  Unknown 3 (1.6) 1 (0.7) 2 (3.6)
Tumor length (cm) 0.976
  Median (range) 5 (0.5–11.0) 5 (0.5–11.0) 5 (2.0–11.0)
Clinical T status 0.306
  T1 8 (4.2) 7 (5.1) 1 (1.8)
  T2 22 (11.4) 15 (10.9) 7 (12.5)
  T3 133 (68.9) 97 (70.8) 36 (64.3)
  T4 28 (14.5) 16 (11.7) 12 (21.4)
  Tx 2 (1.0) 2 (1.5) 0 (0.0)
Clinical n status 0.468
  N0 49 (25.4) 33 (24.1) 16 (28.6)
  N1 141 (73.1) 102 (74.4) 39 (69.6)
  Nx 3 (1.5) 2 (1.5) 1 (1.8)
Clinical M status 0.373
  M0 178 (92.2) 128 (93.4) 50 (89.3)
  M1a 15 (7.8) 9 (6.6) 6 (10.7)
Overall clinical disease
  Stage 0.749
   I 5 (2.6) 4 (2.9) 1 (1.8)
   II 49 (25.4) 36 (26.3) 13 (23.2)
   III 117 (60.6) 84 (61.3) 33 (58.9)
   IV 15 (7.8) 9 (6.6) 6 (10.7)
   X 7 (3.6) 4 (2.9) 3 (5.4)
(Continued )
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after CRT, 12 cases received salvage surgery, 10 cases received 
salvage CRT, 17 cases received salvage chemotherapy and 
the other 30 cases had observation because of poor perfor-
mance status. The incidence of any local failure was lower in 
the high-dose group than that in the low-dose group (17.9% 
versus 34.3%, p = 0.024), and the difference of any local or 
regional failure between the two groups was marginal sig-
nificant (p = 0.049, Table 2). No significant differences were 
found between groups in regional failure, distant metastasis 
failure, or death from ESCC (p > 0.05, Table 2).
Local Control and Survival
The 5-year LRFFS rates seemed higher in high-dose 
group (68.7%) than those in the low-dose group (55.9%), 
which was presented to be a marginal difference (p = 0.052). 
No differences was found between the two groups in terms 
of 5-year DMFS rates (60.6% high versus 62.7% low, 
p = 0.471), 5-year DFS rates (52.0% high versus 41.1% low, 
p = 0.231), or 5-year OS rates (41.7% high versus 33.0% 
low, p = 0.617) (Fig. 1). For the 150 PET-staged patients, no 
5-year OS benefit was found for the high-dose group (n = 38) 
compared with the low-dose group (n = 112) (43.7% high 
versus 33.5% low, p = 0.344).
Toxicity
The incidence and severity of treatment-related toxic-
ity are presented in Table 3. The rate of grade 3 skin reac-
tions (12.5% versus. 2.2%, p < 0.001) and grade greater than 
Baseline maximum PET SUV, 0.101
  Median (range) 14.5 (0.0–51.0) 13.7 (0.0–51.0) 18.9 (6.2–42.0)
Induction chemotherapy 0.578
  No 147 (76.2) 106 (77.4) 41 (73.2)
  Yes 46 (23.8) 31 (22.6) 15 (26.8)
Response to induction chemotherapy 0.631
  Responseb 34 (73.9) 20 (64.5) 14 (93.3)
  Nonresponsec 5 (10.9) 4 (12.9) 1 (6.7)
  Not evaluable 7 (15.2) 7 (22.6) 0 (0.0)
Radiotherapy modality 0.016
  3DCRT 84 (43.5) 61 (44.5) 23 (41.1)
  IMRT 80 (41.52) 50 (36.5) 30 (53.6)
  Proton 29 (15.0) 26 (19.0) 3 (5.3)
Radiotherapy dose (Gy) <0.001
  Median (range) 50.4 (41.4–66.0) 50.4 (41.4–50.4) 60.0 (52.2–66.0)
Clinical response of primary tumor 0.975
  Complete 57 (29.5) 39 (28.5) 18 (32.1)
  Partial 87 (45.1) 61 (44.5) 26 (46.4)
  Minor 13 (6.7) 9 (6.6) 4 (7.1)
  None 11 (5.7) 9 (6.6) 2 (3.6)
  Progressive disease 5 (2.6) 4 (2.9) 1 (1.8)
  Not evaluable 20 (10.4) 15 (10.9) 5 (9.0)
PET complete response 0.148
  No 95 (49.2) 73 (53.3) 22 (39.3)
  Yes 22 (11.4) 16 (11.7) 6 (10.7)
  Unknown 76 (39.4) 48 (35.0) 28 (50.0)
Post-CRT maximum PET SUV, 0.740
  Median (range) 4.9 (0.0–18.4) 4.9 (0.0–18.4) 4.7 (2.0–13.1)
Post-CRT EGD response 0.234
  No residual 122 (63.2) 91 (66.4) 31 (55.4)
  Residual 19 (9.9) 14 (10.2) 5 (8.9)
  Not done 52 (26.9) 32 (23.4) 20 (35.7)
aTumor location: proximal, cervical, and the upper third of the thoracic esophagus; middle: the middle third of the thoracic esophagus; distal: the remaining part of the esophagus.
bResponse: complete, partial or minor response.
cNonresponse: no change or tumor progression.
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or equal to 3 esophageal stricture (32.1% versus.18.2%, p = 
0.037) was higher in the high-dose group than that in the 
low-dose group (Table 3). Otherwise, no significant differ-
ences were observed between the two groups in rates of other 
toxicities. Seven patients died of treatment-related causes in 
the low-dose group (5.1%) versus two patients (3.6%) in 
the high-dose group. Of those nine treatment-related deaths, 
the two in the high-dose group were because of esophageal 
fistula (one at 1 month after 60 Gy and the other at 1 year 
after 60 Gy); four in the low-dose group were from pneumo-
nitis (within 3 months after 50.4 Gy), and the three others 
from the low-dose group were due to weight loss, severe 












Any local failure 57 (29.5) 47 (34.3) 10 (17.9) 0.024
Any regional failure 40 (20.7) 31 (22.6) 9 (16.1) 0.336
Both local and regional failure 28 (14.5) 23 (16.8) 5 (8.9) 0.183
Any local or regional failure 69 (35.8) 55 (40.1) 14 (25.0) 0.049
Distant metastasis 59 (30.6) 39 (28.5) 20 (35.7) 0.390
Any failure 96 (49.7) 71 (51.8) 25 (44.6) 0.428
Death from ESCC 74 (38.3) 54 (39.4) 20 (35.7) 0.745
Death from other causea 49 (25.4) 35 (25.6) 14 (25.0) 1.000
Any death 123 (63.7) 89 (65.0) 34 (60.7) 0.622
aDeath related to treatment, second cancer, pneumonitis and respiratory failure, other severe medical disease, or no specific reason given.
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DISCUSSION
In the current retrospective analysis, we found that 
local tumor control was improved by higher dose of greater 
than 50.4 Gy at the consequence of increased toxicity without 
impact on OS among patients with ESCC. We used modern 
radiation techniques in all cases, with 98% of the patients com-
pleted radiotherapy without a prolonged break. It is uncertain 
why local control benefit was not seen in RTOG 94-05 study 
because a radiation dose-response relationship, within a cer-
tain range, is believed to exist for most types of tumors.20 For 
esophageal carcinoma, there is also some clinical evidence to 
support that higher radiation dose may bring better tumor local 
control.8,21 One review of 26 preoperative concurrent CRT tri-
als (with fluorouracil- and/or cisplatin-based chemotherapy), 
which included 1335 patients, showed that higher doses (within 
a range of 20‒60 Gy) correlated with higher rates of pCR in 
esophageal carcinoma.14 Another study (n = 69) also suggested 
that a higher radiation dose concurrent with cisplatin/fluoroura-
cil chemotherapy was associated with increased local-regional 
control and even better survival in the range of 30 to 64.8 Gy.12 
However, most of the single trials mentioned above were with 
a small sample sizes (22–143 cases) or included multiple his-
tologic types. Because different histologic types of esophageal 
carcinoma seem to have different radiosensitivity,22 we focused 
here only on ESCC, which is also the histologic type in the 
older randomized trials as in RTOG 94-05. We found that, in 
our 193 ESCC patients, local tumor control was improved by a 
higher dose of greater than 50.4 Gy without an impact on OS. 
Collectively, these findings suggest that a better tumor local 
control might be expected with a higher radiation dose than 
50.4 Gy delivered in modern radiation techniques and concur-
rent with effective chemotherapy in ESCC.
The “standard procedure” for determining whether CRT 
has effectively eradicated tumor cells is a pathologic response. 
Bollschweiler et al22 reviewed 16 trials of preoperative CRT 
with cisplatin and fluorouracil and, reported that with a radia-
tion dose of 20 to 46 Gy the median pCR rate for ESCC was 
only 23.7%. Such a low pCR rate may be because of the many 
outdated trials using inadequate doses of radiation or fluoro-
uracil.22 We reviewed the results from prospective trials during 
the past 10 years and listed in Table 4.23–25 With standard-dose 
chemotherapy, a preoperative radiation dose of 41.4 to 45.6 
Gy produced pCR rates of 40% to 48.6% in ESCC. We con-
firmed this result in a small cohort of 37 patients with ESCC 
at our institution who underwent surgery after CRT treated 
with radiation doses of 45 to 50.4 Gy. For these patients, the 
pCR rate was 54.1% (20 of 37) (Table 4). So using effective 
chemotherapy and modern radiation techniques, the pCR rate 
for radiation doses between 41.4 and 50.4 Gy can actually be 
quite high, but even at 45% to 50% pCR rate it is still inad-
equate to achieve a satisfactory tumor local control for defini-




No. of  
Patients Radiation Dosage Chemotherapy Regimen
No. of Patients 
(%) with pCR
van Hagen et al 23 37 41.4 Gy in 23 fractions in 31 days Carboplatin, paclitaxel 18 (48.6)
Pera et al24 10 45.0 Gy in 25 fractions in 33 days Oxaliplatin, cisplatin, fluorouracil 4 (40.0)
Lee et al25 35 45.6 Gy in 38 fractions in 25 days Cisplatin, fluorouracil 15 (42.9)
Our data 37 45.0‒50.4 in 25‒28 fractions in 33–38 days Cisplatin or taxol or oxaliplatin, 
fluorouracil
20 (54.1)
Total 119 41.1‒50.4 Gy (Various) 57 (47.9)
pCR, pathologic complete response.
TABLE 3.  Treatment Toxicity
Toxicity
Low-Dose Group (≤50.4 Gy) (n = 137) High-Dose Group (>50.4 Gy) (n = 56)
p  
ValueGrade 0–1 Grade 2 Grade 3 Grade 4 Grade 5 Grade 0–1 Grade 2 Grade 3 Grade 4 Grade 5
Weight loss 115 (83.9) 18 (13.1) 3 (2.2) 0 (0.0) 1 (0.7) 46 (82.1)  9 (16.1) 1 (1.8) 0 (0.0) 0 (0.0) 0.896
Fatigue 82 (59.9) 48 (35.0) 7 (5.1) 0 (0.0) 0 (0.0) 35 (62.5) 18 (32.1) 3 (5.4) 0 (0.0) 0 (0.0) 0.928
Dysphagia 54 (39.4) 52 (38.0) 30 (21.9) 1 (0.7) 0 (0.0) 23 (41.1) 27 (48.2)  6 (10.7) 0 (0.0) 0 (0.0) 0.212
Esophagitis 56 (40.9) 53 (38.7) 26 (19.0) 1 (0.7) 1 (0.7) 21 (37.5) 25 (44.6)  10 (17.9) 0 (0.0) 0 (0.0) 0.899
Nausea  84 (61.3) 36 (26.3) 17 (12.4) 0 (0.0) 0 (0.0) 37 (66.1) 17 (30.4) 2 (3.6) 0 (0.0) 0 (0.0) 0.166
Anorexia 107 (78.1) 27 (19.7) 3 (2.2) 0 (0.0) 0 (0.0) 47 (83.9) 8 (14.3) 1 (1.8) 0 (0.0) 0 (0.0) 0.755
Skin reaction 117 (85.4) 17 (12.4) 3 (2.2) 0 (0.0) 0 (0.0) 34 (60.7) 15 (26.8)  7 (12.5) 0 (0.0) 0 (0.0) <0.001
Pneumonitis 123 (89.8) 5 (3.6) 4 (2.9) 1 (0.7) 4 (2.9) 54 (96.4) 2 (3.6) 0 (0.0) 0 (0.0) 0 (0.0) 0.597
Lung fibrosis 133 (97.1) 2 (1.5) 0 (0.0) 2 (1.5) 0 (0.0) 56 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1.000
Fistula 134 (97.8) 0 (0.0) 1 (0.7) 2 (1.5) 0 (0.0) 54 (96.4) 0 (0.0) 0 (0.0) 0 (0.0) 2 (3.6) 0.160
Stricture 103 (75.2) 9 (6.6) 23 (16.8) 1 (0.7) 1 (0.7) 38 (67.9) 0 (0.0)  17 (30.4) 1 (1.8) 0 (0.0) 0.037
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dose might be indicated in such ESCC patients because our 
current study did find an improved local control with a higher 
dose of greater than 50.4 Gy.
Guidelines from the National Comprehensive Cancer 
Network,26 based largely on a few published retrospective 
studies,15,16,27 suggest that the location of the tumor within the 
esophagus may dictate the radiation dose; those guidelines rec-
ommend that higher doses (60–66 Gy) are appropriate for cer-
vical esophageal carcinoma.27 With regard to toxicity, the use 
of modern radiation techniques has allowed the safe escalation 
of radiation doses to ESCC while minimizing the toxicity of 
treatment.28,29 However, in our study, the rates of grade greater 
than or equal to 3 skin reaction and esophageal stricture were 
still higher in the high-dose group. Although the increased skin 
toxicity could also be partly explained by the more proximal 
tumor in the high-dose group where skin is nearer to the PTV, 
our results still suggest that the patients’ quality of life may 
have been worse with the high-dose radiation; unfortunately, 
that supposition cannot be tested with the data available to us.
Our study did have some limitations, among them the 
retrospective nature of the analysis, with which we could not 
account for all possible biases as to how patients were treated 
in the various subgroups. First, we cannot fully account for all 
the reasons why some patients were treated to higher doses than 
others. For the most part, we believe that the choice of who got 
higher (or lower) doses was not based on patient factors but 
rather on physician bias. In our institution, cervical ESCC is 
often treated by head and neck physicians to a dose of 66 Gy; 
however, some of the patients with the similar characteristics 
will be treated in the thoracic or gastrointestinal service with 
a lower dose (45‒60 Gy) (unpublished observation). Second, 
because the squamous cell carcinoma is not a predominant type 
of esophageal carcinoma in the United States, the relative small 
sample size is another limitation of our study. Although the 
high-dose group showed a higher tumor local control rate than 
the low-dose group in our data analysis, we only found a mar-
ginal significant difference in LRFFS between the two groups. 
Larger sample size studies are needed to confirm our results.
In conclusion, we found that radiation doses in excess of 
50.4 Gy improved tumor local control but not OS for patients 
with ESCC. Although the use of advanced radiation delivery 
approaches reduced the overall incidence of high-grade toxic-
ity, we did find higher rates of grade greater than 3 skin reaction 
and esophageal stricture among patients receiving greater than 
50.4 Gy than among those receiving lower doses. Considering 
the potential better tumor local control but a severer toxicity 
incidence of higher radiation dose in ESCC, we recommend that 
the optimal definitive radiation dose should be managed on an 
individual basis. When concurrent with chemotherapy, for the 
middle/distal ESCC, as a much more amendable location for sal-
vage surgery, the radiation doses for definitive purpose should 
not exceed 50.4 Gy; while for the proximal ESCC, higher dose 
greater than 50.4 Gy may help improve tumor local control.
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